Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Revenue
86
21
23
19
21
40
Revenue Growth (YoY)
-49%
-48%
-50%
-56.99%
-43%
-11%
Cost of Revenue
43
9
12
10
11
21
Gross Profit
42
11
11
9
10
19
Selling, General & Admin
98
18
25
26
28
38
Research & Development
22
2
7
6
6
11
Operating Expenses
121
20
33
32
34
50
Other Non Operating Income (Expenses)
-1
-5
0
-2
4
3
Pretax Income
-87
-14
-22
-32
-18
-26
Income Tax Expense
-37
0
-35
-1
0
0
Net Income
78
127
19
-34
-33
-26
Net Income Growth
-159%
-588%
-156%
31%
-27%
-67%
Shares Outstanding (Diluted)
388.2
388.2
385.08
382.63
380.49
378.22
Shares Change (YoY)
3%
3%
3%
3%
2%
28.99%
EPS (Diluted)
0.2
0.32
0.03
-0.08
-0.08
-0.06
EPS Growth
-156%
-565%
-140%
14%
-35%
-74%
Free Cash Flow
-94
-47
-1
-23
-22
-35
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
48.83%
52.38%
47.82%
47.36%
47.61%
47.5%
Operating Margin
-90.69%
-42.85%
-91.3%
-121.05%
-109.52%
-75%
Profit Margin
90.69%
604.76%
82.6%
-178.94%
-157.14%
-65%
Free Cash Flow Margin
-109.3%
-223.8%
-4.34%
-121.05%
-104.76%
-87.5%
EBITDA
-70
-8
-20
-22
-20
-26
EBITDA Margin
-81.39%
-38.09%
-86.95%
-115.78%
-95.23%
-65%
D&A For EBITDA
8
1
1
1
3
4
EBIT
-78
-9
-21
-23
-23
-30
EBIT Margin
-90.69%
-42.85%
-91.3%
-121.05%
-109.52%
-75%
Effective Tax Rate
42.52%
0%
159.09%
3.12%
0%
0%
Follow-Up Questions
What are Standard BioTools Inc's key financial statements?
According to the latest financial statement (Form-10K), Standard BioTools Inc has a total asset of $0, Net loss of $0
What are the key financial ratios for LAB?
Standard BioTools Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Standard BioTools Inc's revenue broken down by segment or geography?
Standard BioTools Inc largest revenue segment is Proteomics, at a revenue of 135,789,000 in the most earnings release.For geography, United States is the primary market for Standard BioTools Inc, at a revenue of 89,900,000.
Is Standard BioTools Inc profitable?
no, according to the latest financial statements, Standard BioTools Inc has a net loss of $0
Does Standard BioTools Inc have any liabilities?
no, Standard BioTools Inc has liability of 0
How many outstanding shares for Standard BioTools Inc?
Standard BioTools Inc has a total outstanding shares of 0